Cantor Fitzgerald Reiterates “Overweight” Rating for Pfizer (NYSE:PFE)

Cantor Fitzgerald reiterated their overweight rating on shares of Pfizer (NYSE:PFE – Free Report) in a research report report published on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $45.00 target price on the biopharmaceutical company’s stock. Several other research analysts also recently weighed in on the stock. Barclays upped their price target on […]

Leave a Reply

Your email address will not be published.

Previous post Capital Investment Counsel Inc Sells 130 Shares of Vanguard S&P 500 ETF (NYSEARCA:VOO)
Next post Nucor (NYSE:NUE) Price Target Lowered to $168.00 at JPMorgan Chase & Co.